Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status
- PMID: 2390470
- PMCID: PMC1971719
- DOI: 10.1038/bjc.1990.241
Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status
Abstract
Monoclonal antibodies 19-9 and C-50 were used to assay the cancer associated tumour antigens CA 19-9 and CA-50 in plasma from patients with confirmed pancreatic cancer, and related to the blood group and Lewis blood cell status. The plasma expressions of CA 19-9 or CA-50 were similar, including cases where the patients had Lewis phenotype Le (a-b-). However, analyses of both the tumour antigens could be used to differentiate the presence of cancer from its absence in Le (a-b-) individuals. The findings indicate that the targets for the monoclonal antibodies 19-9 and C-50 are similar. The practical implications of these findings are discussed.
Similar articles
-
Expression of blood group-related antigens in normal and malignant pancreatic tissue correlated with genotype of the patient defined by saliva glycoprotein.Cancer. 1993 Jan 1;71(1):71-81. doi: 10.1002/1097-0142(19930101)71:1<71::aid-cncr2820710113>3.0.co;2-4. Cancer. 1993. PMID: 8416729
-
Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type.Cancer Res. 1988 Oct 1;48(19):5422-6. Cancer Res. 1988. PMID: 3166398
-
Comparative study on the expression of the blood group antigens Le(a), Le(b), Le(x), Le(y) and the carbohydrate antigens CA19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma.Acta Histochem Suppl. 1990;40:143-6. Acta Histochem Suppl. 1990. PMID: 2091042 No abstract available.
-
Role of tumour markers, cytogenetics.Ann Oncol. 1999;10 Suppl 4:145-9. Ann Oncol. 1999. PMID: 10436809 Review.
-
[2-->6 Sialyl Le(a) antigen].Nihon Rinsho. 2005 Aug;63 Suppl 8:663-8. Nihon Rinsho. 2005. PMID: 16149606 Review. Japanese. No abstract available.
Cited by
-
Case Report: Overcoming challenges in pancreatic cancer with liver metastases: a personalized therapeutic odyssey of TACE, ablation, and immunotherapy.Front Immunol. 2023 Oct 11;14:1275782. doi: 10.3389/fimmu.2023.1275782. eCollection 2023. Front Immunol. 2023. PMID: 37885893 Free PMC article.
-
Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.Br J Cancer. 1991 Nov;64(5):899-902. doi: 10.1038/bjc.1991.422. Br J Cancer. 1991. PMID: 1931612 Free PMC article.
-
The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.Br J Cancer. 1994 Mar;69(3):515-9. doi: 10.1038/bjc.1994.93. Br J Cancer. 1994. PMID: 7510116 Free PMC article.
-
Monoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts.Neoplasia. 2004 Nov-Dec;6(6):713-24. doi: 10.1593/neo.04298. Neoplasia. 2004. PMID: 15720797 Free PMC article.
-
Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.J Cancer Res Clin Oncol. 1994;120(8):494-7. doi: 10.1007/BF01191804. J Cancer Res Clin Oncol. 1994. PMID: 8207049 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical